Pricing Log in Create free account
Friday 6 November 2026 Export SIGA’s income statement to Excel — free account

Siga Technologies Inc.

SIGA Healthcare Drug Manufacturers Specialty & Generic

Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024.

Revenue
−49.5%
EPS
−66.0%
Free cash flow
−76.0%

Quarter to June 2026, against a year earlier

3.10 0.13 +4.38%
Market cap
$213.4M
P/E
0.0×
Fwd P/E
60.8×
Dividend yield
0.00%
F-score
5/9
Altman Z
14.28
Beneish M
−4.02
Dividend safety
36/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 42.68%

Capital & Financial Ratios $m

Size
Market Cap 213.40
Revenue ttm 53.66
Net income ttm (2.79)
Free cash flow ttm (20.17)
Net debt Q (117.58)
Valuation
P/E 0.00
Forward P/E 60.80 (above 35: high)
Price / sales 3.97
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.29
Financial health
Current ratio Q 21.72 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (1.48)
Growth
Revenue growth Q −49.45% (below 0%: shrinking)
Operating income growth Q −69.56% (below 0%: shrinking)
EPS, this year −18.29% (below 0%: weak)
EPS, next year A +153.73% (at or above 15%: strong)
Revenue, next year A −36.71% (below 0%: weak)
EPS, past 5 yrs −14.73% (below 0%: weak)
EPS, next 5 yrs A +1.00%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.7×, against a ten-year median of 4.8×; over the ten years it ranged from −10.4× in 2016 to 97.7× in 2018.
P/S against its own 10 years 41.03%
10-year low 10-year high
P/B against its own 10 years 0.44%
10-year low 10-year high
EV/Sales against its own 10 years 47.79%
10-year low 10-year high

Dividends

Yield
0.00%
Annual rate
0.00
Payout ratio
—
  1. 0.60 ’26e
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 150 155 155 118
Receivables 21 21 3 7
Inventory 64 50 49 41
Other — — — —
239 231 213 170
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — — —
54 25 18 8

Compound Annual Growth %

10y 5y 3y
Sales 27.74% (5.42%) (5.13%)
Cash Flow 14.62% (9.48%) 1.47%
Earnings 0.00% (16.20%) (11.78%)
Book Value 0.00% 8.90% 5.33%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY14 Estimate 0.22 Actual −0.06

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY13 −0.09 −0.10 Miss by 0.01
Q3 FY13 0.87 −0.09 Miss by 0.96
Q4 FY13 0.62 −0.07 Miss by 0.69
Q1 FY14 0.22 −0.06 Miss by 0.28

EPS $

Mar Jun Sep Dec Year
’26 (0.05) 0.17 — — —
’25 (0.01) 0.49 (0.09) (0.08) 0.32
’24 0.14 0.03 0.02 0.63 0.82
’23 (0.01) (0.04) (0.01) 1.01 0.95
’22 0.00 0.03 0.45 (0.01) 0.46
’21 (0.01) 0.00 (0.04) 0.98 0.91
’20 (0.11) 0.26 0.31 0.26 0.71
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 6 41 — — —
’25 7 81 3 4 95
’24 25 22 10 81 139
’23 8 6 9 116 140
’22 11 17 72 11 111
’21 5 9 5 115 134
’20 3 40 44 38 125
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) 15 — — —
’25 7 63 (10) (17) 43
’24 (6) 6 (7) 56 49
’23 24 (4) (5) 79 95
’22 57 (2) (5) (8) 42
’21 (5) (1) 2 16 11
’20 3 (9) 31 46 72
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) 15 — — —
’25 7 63 (10) (17) 43
’24 (6) 6 (7) 56 49
’23 24 (4) (5) 79 95
’22 57 (2) (5) (8) 42
’21 (5) (1) 2 16 11
’20 3 (9) 31 46 72
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 15 12 477 27 125 134 111 140 139 95 54 +22.7% 60 162 — +30.9%
Gross margin, % 100.00 100.00 80.03 93.33 88.16 87.58 90.58 87.26 77.44 68.59 54.35 (31.4) pt
EBT (40) (38) 412 (10) 74 89 44 88 76 30 (6) n/m
EBT margin, % (264.78) (312.41) 86.29 (38.06) 58.83 66.81 39.84 62.73 54.84 32.12 (10.27) +296.9 pt
Net income (40) (36) 422 (7) 56 69 34 68 59 23 (3) n/m
Per share, $
Per share, $ Revenue 0.26 0.16 5.97 0.33 1.58 1.77 1.52 1.96 1.95 1.32 0.75 +19.7%
Earnings (0.69) (0.46) 5.28 (0.09) 0.71 0.92 0.46 0.95 0.83 0.33 (0.04) n/m
Cash flow (2.04) (0.23) 0.86 (0.22) 0.90 0.15 0.57 1.33 0.68 0.61 (0.28) n/m
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 +32.4%
Free cash flow (2.04) (0.23) 0.86 (0.22) 0.90 0.15 0.57 1.33 0.68 0.60 (0.28) n/m
Book value (5.03) (4.10) 1.29 1.21 1.64 2.31 2.33 2.76 3.03 2.78 2.30 n/m
Shares, m 57 79 80 81 79 75 73 71 71 72 72 +2.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 1.50 0.00 10.10 8.07 15.12 6.10 7.33 18.28 0.00 6.6
P/S 11.18 30.86 1.32 14.45 4.61 4.24 4.63 2.97 3.09 4.62 3.97 8.2
P/B 0.00 0.00 6.14 3.95 4.44 3.25 3.01 2.11 1.98 2.20 1.29 2.7
EV/Sales 13.16 34.32 1.25 14.38 4.94 4.66 5.17 3.03 3.11 4.66 4.74 8.9
EV/FCF (1.69) (22.76) 8.68 (21.09) 8.63 54.37 13.78 4.48 8.86 10.23 (12.40) 6.4
Cash, $m
Cash, $m Operating cash flow (117) (18) 69 (18) 72 11 42 95 49 43 (20) n/m
Capex 0 0 0 0 0 0 — 0 0 0 0 +35.0%
Free cash flow (117) (18) 69 (18) 72 11 42 95 49 43 (20) n/m
Balance, $m
Balance, $m Working capital 62 31 110 88 133 178 164 185 206 195 163 +13.6%
Net debt 28 40 (37) (81) (118) (103) (99) (150) (155) (155) (118) n/m
Shareholders’ equity (287) (323) 103 98 130 174 170 197 216 199 165 n/m
Returns, %
Returns, % ROA (22.90) (23.71) 242.34 (3.60) 32.34 38.10 16.55 30.29 23.75 10.04 (1.36) +32.9 pt
ROIC 0.00 0.00 334.46 (8.62) 443.69 78.23 37.39 111.88 72.41 33.78 (14.59) +33.8 pt
ROE 13.88 11.87 (383.07) (7.22) 49.51 45.68 19.68 37.09 28.70 11.23 (1.49) (2.7) pt
People
People Employees 36 37 41 41 42 39 39 45 46 49 — +3.5%
Revenue/emp, $m 0.42 0.33 11.64 0.65 2.98 3.43 2.84 3.11 3.02 1.93 — +18.6%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Siga Technologies Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EBS Emergent Biosolutions Inc. $300.8M — (loss-making) — (loss-making) −52.40% (below 0%: shrinking) n/m +1,892.98% (above 0%: growing) 26.55% (33.91%) Compare
CGC Canopy Growth Corporation $283.5M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%) Compare
ANIK Anika Therapeutics Inc. $258.7M — (loss-making) 599× +15.56% (above 0%: growing) n/m +61.58% (above 0%: growing) 65.15% 9.06% Compare
BIOA BioAge Labs, Inc. $254.3M — (loss-making) — (loss-making) −85.49% (below 0%: shrinking) n/m −92.81% (below 0%: shrinking) 100.00% (12,554.03%) Compare
LFCR Lifecore Biomedical, Inc. $242.6M — (loss-making) — (loss-making) −18.60% (below 0%: shrinking) n/m +27,684.00% (above 0%: growing) 26.96% (3.53%) Compare
SIGA Siga Technologies Inc. $213.4M — (loss-making) 60.8× −49.45% (below 0%: shrinking) −66.00% (below 0%: shrinking) −75.95% (below 0%: shrinking) 57.17% 33.91%
ADCT ADC Therapeutics SA $209.4M — (loss-making) — (loss-making) +2.17% (above 0%: growing) n/m +50.98% (above 0%: growing) 87.80% (132.03%) Compare
GLAS Glass House Brands Inc. $172.7M — (loss-making) — (loss-making) −1.24% (below 0%: shrinking) n/m −123.36% (below 0%: shrinking) 33.54% (6.37%) Compare
AKBA Akebia Therapeutics, Inc. $117.9M — (loss-making) — (loss-making) −37.20% (below 0%: shrinking) n/m −94.20% (below 0%: shrinking) 82.76% (31.06%) Compare
Median of peers $248.4M — — −9.92% — −20.91% 49.34% (29.15%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 28 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.24m 3.74m 116.00
2024 4.59m 5.64m 104.00
2023 1.83m 1.83m 88.00
2022 1.74m 1.74m 107.00
2021 1.69m 1.69m 103.00

Ownership

Directors and executive officers, together 2.73%
MacAndrews & Forbes Incorporated 33.68%
John Latane Lewis, IV 7.35%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Siga Technologies Inc. (SIGA) Latest News

29 Oct

Impact 3 · · GlobeNewswire

28 Oct

Impact 3 · · GlobeNewswire

6 Sep

Impact 3 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 · · Simply Wall St.
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat
Impact 3 · transcript

6 Aug

Impact 4 · · GuruFocus.com transcript
Impact 3 ·

15 May

Impact 4 · · Simply Wall St.

14 May

Impact 3 ·

8 May

Impact 4 · · MarketBeat

7 May

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · GlobeNewswire

15 Mar

Impact 3 · · Simply Wall St.

14 Mar

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

10 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 3 ·

27 Jan

Impact 4 · · Simply Wall St.

29 Dec

Impact 4 · · Simply Wall St.

24 Nov

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

7 Nov

Impact 4 · · GuruFocus.com transcript

6 Nov

Impact 3 · · GlobeNewswire

30 Oct

Impact 3 ·

13 Oct

Impact 4 · · Simply Wall St.

10 Sep

Impact 4 ·
stockrow.com/SIGA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com